Abstract:BackgroundLeukocyte-associated immunoglobulin-like receptor 1 (LAIR-1) is an immune inhibitory receptor that binds collagen-like domains commonly found in extracellular matrix (ECM) collagens and complement component C1q. LAIR-1 is expressed on several immune cell types including activated T cells, B cells, NK cells, dendritic cells, and macrophages. Numerous cancer types including gastric, colon, ovarian, bladder, and others, upregulate collagens which enhances tumor growth, metastases, and invasion while actively suppressing antitumor immunity. While a soluble decoy, LAIR-2, is expressed in humans and competes with LAIR-1 for binding of collagen domains, excess LAIR ligands in the tumor often result in an immune suppressive environment.MethodsHere, we report on a novel immunotherapy approach combining NC410, a novel fusion protein consisting of two LAIR-2 molecules grafted on to an IgG1 antibody backbone, capable of targeting the tumor ECM and blocking LAIR-1 signaling; and bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of the human transforming growth factor β receptor II (TGF-βRII or TGF-β ”trap”) fused via a flexible linker to the C-terminus of each heavy chain of an IgG1 antibody blocking programmed death ligand 1 (anti–PD-L1).ResultsWe have demonstrated that the combination of NC410 and bintrafusp alfa more effectively controls in vivo tumor growth of the collagen rich MC38 colon and EMT6 mammary carcinomas compared to either monotherapy. We demonstrate that this potent anti-tumor immune response is propagated through the synergy of activated tumor infiltrating lymphocytes and a repolarization of myeloid cells in the tumor microenvironment. MC38 tumors treated with the combination of NC410 plus bintrafusp alfa contained higher numbers of infiltrating T cells, NK cells, and M1 polarized macrophages.ConclusionsThis study highlights the synergy of reshaping the large suppressive myeloid cell populations often present in tumors with activation of adaptive T-cell immune responses dampened by checkpoint inhibition. The results also provide the rationale for the future evaluation of this combination therapy in the clinic.

Conation: a missing link in the strengths perspective.

A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody

Epidemiology of endemic cholera.

PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy

Lymphocyte activation gene-3 as a candidate target for combo anti-programmed death-(ligand) 1 therapy of cancer

The immune checkpoint receptor LAG3: Structure, function, and target for cancer immunotherapy

LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation

Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer

The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application

570 Blockade of the Inhibitory Collagen Receptor LAIR-1, PD-L1, and TGF-β Promotes Anti-Tumor Activity Through T Cell Activation and Myeloid Cell Polarization

LAG3 blockade coordinates with microwave ablation to promote CD8+ T cell-mediated anti-tumor immunity

Lag3: From Bench to Bedside

Structural basis for mouse LAG3 interactions with the MHC class II molecule I-Ab

Cutting Edge: LAG3 Dimerization Is Required for TCR/CD3 Interaction and Inhibition of Antitumor Immunity

Screening, expression and anti-tumor functional identification of anti-LAG-3 nanobodies

Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples

LAG3 landscape in solid tumors and its association with immunotherapy outcomes in non-small cell lung cancer.

A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses

Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

Antagonist anti-LIF antibody derived from naive human scFv phage library inhibited tumor growth in mice

Novel Anti-Cd20 Antibody Tgla with Enhanced Antibody-Dependent Cell-Mediated Cytotoxicity Mediates Potent Anti-Lymphoma Activity